.png)
Commercialization at UHN is pleased to offer an express Confidential Disclosure Agreement (CDA)/Non-Disclosure Agreement (NDA) for parties wishing to exchange confidential information with UHN to evaluate potential research collaborations or IP licensing and commercialization opportunities. This is a non-negotiable agreement intended to streamline the CDA/NDA execution process. Please be advised that any modifications requested beyond the standard terms may result in extended lead times compared to the current express track.
Please use this form if your organization is a hospital, CRO or Commercial entity and you wish to use STOP-BANG in routine patient screening/clinical care or for industry-sponsored research or for a clinical trial
A UHN representative will review all submitted requests to ensure the fields are completed correctly. If approved, a completed express license agreement will be sent via email for signature to the signatory designated above.